Transparency too little, too late? Why and how Health Canada should make clinical data and regulatory decision-making open to scrutiny in the face of COVID-19.
作者信息
Edmonds Sterling, MacGregor Andrea, Doll Agnieszka, Vural Ipek Eren, Graham Janice, Fierlbeck Katherine, Lexchin Joel, Doshi Peter, Herder Matthew
机构信息
Schulich School of Law, Dalhousie University.
Department of Pediatrics (Infectious Diseases), Dalhousie University.
出版信息
J Law Biosci. 2020 Nov 19;7(1):lsaa083. doi: 10.1093/jlb/lsaa083. eCollection 2020 Jan-Jun.
Abstract
摘要
相似文献
1
Transparency too little, too late? Why and how Health Canada should make clinical data and regulatory decision-making open to scrutiny in the face of COVID-19.透明度不足，为时已晚？面对新冠疫情，加拿大卫生部为何以及应如何使临床数据和监管决策接受审查。
J Law Biosci. 2020 Nov 19;7(1):lsaa083. doi: 10.1093/jlb/lsaa083. eCollection 2020 Jan-Jun.
2
A compromise too far: a review of Canadian cases of direct-to-consumer advertising regulation.走得太远的妥协：对加拿大直接面向消费者广告监管案例的回顾
Int J Risk Saf Med. 2014;26(4):213-25. doi: 10.3233/JRS-140635.
3
Trust and transparency in times of crisis: Results from an online survey during the first wave (April 2020) of the COVID-19 epidemic in the UK.信任与透明度在危机时期：英国 COVID-19 疫情第一波（2020 年 4 月）期间在线调查结果。
PLoS One. 2021 Feb 16;16(2):e0239247. doi: 10.1371/journal.pone.0239247. eCollection 2021.
4
Toward a jurisprudence of drug regulation.迈向药品监管的法理学
J Law Med Ethics. 2014 Summer;42(2):244-62. doi: 10.1111/jlme.12139.
5
A real-time policy dashboard can aid global transparency in the response to coronavirus disease 2019.实时政策仪表板可以帮助提高全球对 2019 冠状病毒病应对措施的透明度。
Int Health. 2020 Sep 1;12(5):373-374. doi: 10.1093/inthealth/ihaa039.
6
Regulatory Decision Making in Canada-Exploring New Frontiers in Patient Involvement.加拿大的监管决策——探索患者参与的新领域
Value Health. 2016 Sep-Oct;19(6):730-733. doi: 10.1016/j.jval.2016.03.1855. Epub 2016 May 6.
7
Pharmacy Internal Controls: A Call for Greater Vigilance during the COVID-19 Pandemic.药房内部控制：呼吁在新冠疫情期间提高警惕
Pharmacy (Basel). 2020 Nov 15;8(4):216. doi: 10.3390/pharmacy8040216.
8
The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond.经济证据在加拿大肿瘤学报销决策中的作用：从拉姆达到更远。
Value Health. 2008 Jul-Aug;11(4):771-83. doi: 10.1111/j.1524-4733.2007.00298.x. Epub 2007 Dec 18.
9
Will virtual multidisciplinary team meetings become the norm for musculoskeletal oncology care following the COVID-19 pandemic? - experience from a tertiary sarcoma centre.在新冠疫情之后，虚拟多学科团队会议会成为肌肉骨骼肿瘤护理的常态吗？——来自一家三级肉瘤中心的经验
BMC Musculoskelet Disord. 2021 Jan 5;22(1):18. doi: 10.1186/s12891-020-03925-8.
10
Summary of a report for Canadian oral health professionals for a safe return to clinical practice during COVID-19.一份面向加拿大口腔健康专业人员的报告摘要，内容是关于在新冠疫情期间安全恢复临床实践。
Can Commun Dis Rep. 2020 Nov 5;46(11-12):374-375. doi: 10.14745/ccdr.v46i1112a01.
引用本文的文献
1
A scoping review of authorisation pathway for COVID19 vaccines among selected countries.选定国家中新冠疫苗授权途径的范围综述。
J Pharm Policy Pract. 2025 Jul 2;18(1):2520861. doi: 10.1080/20523211.2025.2520861. eCollection 2025.
2
How to use the regulatory data from Health Canada for secondary analyses on new drugs, biologics and vaccines.如何利用加拿大卫生部的监管数据对新药、生物制品和疫苗进行二次分析。
BMJ Evid Based Med. 2024 May 22;29(3):187-193. doi: 10.1136/bmjebm-2023-112475.
3
Biopharmaceutical Financialization and Public Funding of Medical Countermeasures (MCMs) in Canada During the COVID-19 Pandemic.在 COVID-19 大流行期间，加拿大的生物制药金融化与医疗对策（MCM）的公共资金投入
Int J Health Policy Manag. 2023;12:6936. doi: 10.34172/ijhpm.2023.6936. Epub 2023 May 27.
4
On what basis did Health Canada approve OxyContin in 1996? A retrospective analysis of regulatory data.1996 年加拿大卫生部批准奥施康定的依据是什么？监管数据的回顾性分析。
Clin Trials. 2022 Oct;19(5):584-590. doi: 10.1177/17407745221108436. Epub 2022 Aug 4.
5
Regulators, Pivotal Clinical Trials, and Drug Regulation in the Age of COVID-19.监管机构、关键临床试验与新冠疫情时代的药品监管
Int J Health Serv. 2021 Jan;51(1):5-13. doi: 10.1177/0020731420979824.
Zotero 插件